Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

Abstract Objectives The SWORD trial is the first multicenter, single arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT) and granulocyte–macrophage colony stimulating factor (GM-CSF) in advanced non-small cell lung cancer (NSC...

Full description

Bibliographic Details
Main Authors: Jianjiao Ni, Yue Zhou, Lin Wu, Xinghao Ai, Xiaorong Dong, Qian Chu, Chengbo Han, Xiaofei Wang, Zhengfei Zhu
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Radiation Oncology
Subjects:
Sintilimab
Stereotactic body radiotherapy (SBRT)
Granulocyte–macrophage colony stimulating factor (GM-CSF)
Non-small cell lung cancer (NSCLC)
Treatment-related adverse event (TRAE)
Online Access:https://doi.org/10.1186/s13014-021-01905-3

Internet

https://doi.org/10.1186/s13014-021-01905-3

Similar Items